Photo from investor.agenusbio.com
Jun 28, 2024, 13:09
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X:
“Impressive pathological response rate (71%, pCR 35%) with neoadjuvant BOT/BAL in MSS colorectal cancer from the update of NEST-1 trial.”
Source: Vittorio Studiale/X
Agenus
Balstilimab
BOT/BAL
BOT/BAL immunotherapy
botensilimab
cancer
colorectal cancer
ESMO
ESMOGI24
European Society for Medical Oncology
Garo Armen
Jennifer Buell
Mehraneh Jafari
metastatic MSS colorectal cancer
MSS CRC
neoadjuvant BOT/BAL
NEST-1 trial
OncoDaily
Oncology
Pashtoon Kasi
Steven O'Day
Vittorio Studiale